HematologyNews.net

Hematology Xagena

Xagena Mappa
Medical Meeting
Dermabase.it
Mediexplorer.it

The results from PANORAMA-1 ( PANobinostat ORAl in Multiple MyelomA ) trial were presented at ASCO meeting, showing a 37% improvement in progression-free survival ( PFS ) when using the investigationa ...


The FDA ( Food and Drug Administration ) has approved a Supplemental Biologic License Application ( sBLA ) for the use of Arzerra ( Ofatumumab ), a CD20-directed cytolytic monoclonal antibody, in comb ...


A group of researchers at the Institute for Research in Immunology and Cancer ( IRIC ) of Université de Montréal discovered a promising new approach to treating leukemia by disarming a gene that is re ...


The Food and Drug Administration ( FDA ) has expanded the approved use of Imbruvica ( Ibrutinib ) for chronic lymphocytic leukemia ( CLL ) patients who have received at least one previous therapy.Chro ...


VMP and Rd are two of the most efficient and widely accepted regimens in the treatment of elderly newly diagnosed multiple myeloma patients. In order to further improve the outcome of elderly patients ...


T-cell depleted HLA-haploidentical hematopoietic stem cell transplantation ( HSCT ) is a suitable option for patients in need of an allograft who lack a HLA-matched donor. Although it offers the advan ...


The medical journal Leukemia has published results from the Phase 2 trial known as PX-171-005, an open-label, multicenter clinical trial evaluating Kyprolis ( Carfilzomib ) for injection in patients w ...


No consensus exists on whether preoperative blood transfusions are beneficial in patients with sickle-cell disease. A study has assessed whether perioperative complication rates would be altered by pr ...


The efficacy of autologous stem-cell transplantation during the first remission in patients with diffuse, aggressive non-Hodgkin's lymphoma classified as high-intermediate risk or high risk on the Int ...


Peripherally inserted central catheters ( PICCs ) are associated with an increased risk of venous thromboembolism. However, the size of this risk relative to that associated with other central venous ...


Two clinical studies published in the New England Journal of Medicine ( NEJM ) suggest that the novel agent Ibrutinib shows real potential as a safe, effective, targeted treatment for adults with chro ...


Hodgkin lymphoma survivors who received certain radiation and chemotherapy regimens were at increased risk of subsequently developing stomach cancer.The study appeared in the Journal of Clinical Oncol ...


Many mutations that contribute to the pathogenesis of acute myeloid leukemia ( AML ) are undefined. The relationships between patterns of mutations and epigenetic phenotypes are not yet clear.Research ...


Rituximab ( MabThera, Rituxan ) plus chemotherapy, most often CHOP ( Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone ), is the first-line standard of care for patients with advanced indolen ...


For patients with smoldering multiple myeloma, the standard of care is observation until symptoms develop. However, this approach does not identify high-risk patients who may benefit from early interv ...